Herpes simplex virus type 1-specific immunity induced by peptides corresponding to an antigenic site of glycoprotein B.
Identifieur interne : 002A18 ( PubMed/Corpus ); précédent : 002A17; suivant : 002A19Herpes simplex virus type 1-specific immunity induced by peptides corresponding to an antigenic site of glycoprotein B.
Auteurs : J C Mester ; S L Highlander ; A P Osmand ; J C Glorioso ; B T RouseSource :
- Journal of virology [ 0022-538X ] ; 1990.
English descriptors
- KwdEn :
- Amino Acid Sequence, Animals, Antibodies, Monoclonal (immunology), Antibody-Dependent Cell Cytotoxicity, Epitopes, Mice, Mice, Inbred Strains, Molecular Sequence Data, Neutralization Tests, Peptides (chemical synthesis), Peptides (immunology), Protein Conformation, Simplexvirus (immunology), Viral Envelope Proteins (immunology).
- MESH :
- chemical , chemical synthesis : Peptides.
- chemical , immunology : Antibodies, Monoclonal, Peptides, Viral Envelope Proteins.
- immunology : Simplexvirus.
- Amino Acid Sequence, Animals, Antibody-Dependent Cell Cytotoxicity, Epitopes, Mice, Mice, Inbred Strains, Molecular Sequence Data, Neutralization Tests, Protein Conformation.
Abstract
Herpes simplex virus (HSV) envelope glycoproteins are the prime targets of adaptive antiviral immunity. Previous investigation identified a protective, neutralizing, glycoprotein B1 (gB-1)-reactive monoclonal antibody (MAb B6) and localized the linear epitope recognized by the MAb to residue 84 of gB-1. Three overlapping peptides (two 20-mers and one 18-mer), together spanning amino acids 63 to 110 of the wild-type sequence of gB-1, were synthesized and analyzed for their ability to stimulate immunity which cross-reacts with HSV-1. All stimulated some level of response. Two peptides, the gB 18-mer and 20.1-mer, were recognized by MAb B6 and HSV-immune antibody but were unable to stimulate virus-neutralizing antibody or serum able to protect against zosteriform spread in vivo. The 20.2-mer peptide, however, which was not recognized by MAb B6 or HSV-generated immune antibody, stimulated the production of neutralizing antibody and serum able to protect against zosteriform spread. Immunization with all of the peptides was able to enhance viral clearance of a low dose of HSV-1 in an ear challenge model and induce antibody reactive in antibody-dependent complement-mediated lysis of HSV-1-infected cells in vitro. These results are the first report of HSV immunity induced by peptides corresponding to gB and indicate that the best immunogen, in terms of stimulating neutralizing antiserum able to protect in vivo against HSV-1, was a peptide not recognized by HSV-immune mechanisms or by the MAb used to localize it.
PubMed: 1698994
Links to Exploration step
pubmed:1698994Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Herpes simplex virus type 1-specific immunity induced by peptides corresponding to an antigenic site of glycoprotein B.</title>
<author><name sortKey="Mester, J C" sort="Mester, J C" uniqKey="Mester J" first="J C" last="Mester">J C Mester</name>
<affiliation><nlm:affiliation>Department of Microbiology, College of Veterinary Medicine, University of Tennessee, Knoxville 37996-0845.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Highlander, S L" sort="Highlander, S L" uniqKey="Highlander S" first="S L" last="Highlander">S L Highlander</name>
</author>
<author><name sortKey="Osmand, A P" sort="Osmand, A P" uniqKey="Osmand A" first="A P" last="Osmand">A P Osmand</name>
</author>
<author><name sortKey="Glorioso, J C" sort="Glorioso, J C" uniqKey="Glorioso J" first="J C" last="Glorioso">J C Glorioso</name>
</author>
<author><name sortKey="Rouse, B T" sort="Rouse, B T" uniqKey="Rouse B" first="B T" last="Rouse">B T Rouse</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="1990">1990</date>
<idno type="RBID">pubmed:1698994</idno>
<idno type="pmid">1698994</idno>
<idno type="wicri:Area/PubMed/Corpus">002A18</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002A18</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Herpes simplex virus type 1-specific immunity induced by peptides corresponding to an antigenic site of glycoprotein B.</title>
<author><name sortKey="Mester, J C" sort="Mester, J C" uniqKey="Mester J" first="J C" last="Mester">J C Mester</name>
<affiliation><nlm:affiliation>Department of Microbiology, College of Veterinary Medicine, University of Tennessee, Knoxville 37996-0845.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Highlander, S L" sort="Highlander, S L" uniqKey="Highlander S" first="S L" last="Highlander">S L Highlander</name>
</author>
<author><name sortKey="Osmand, A P" sort="Osmand, A P" uniqKey="Osmand A" first="A P" last="Osmand">A P Osmand</name>
</author>
<author><name sortKey="Glorioso, J C" sort="Glorioso, J C" uniqKey="Glorioso J" first="J C" last="Glorioso">J C Glorioso</name>
</author>
<author><name sortKey="Rouse, B T" sort="Rouse, B T" uniqKey="Rouse B" first="B T" last="Rouse">B T Rouse</name>
</author>
</analytic>
<series><title level="j">Journal of virology</title>
<idno type="ISSN">0022-538X</idno>
<imprint><date when="1990" type="published">1990</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Amino Acid Sequence</term>
<term>Animals</term>
<term>Antibodies, Monoclonal (immunology)</term>
<term>Antibody-Dependent Cell Cytotoxicity</term>
<term>Epitopes</term>
<term>Mice</term>
<term>Mice, Inbred Strains</term>
<term>Molecular Sequence Data</term>
<term>Neutralization Tests</term>
<term>Peptides (chemical synthesis)</term>
<term>Peptides (immunology)</term>
<term>Protein Conformation</term>
<term>Simplexvirus (immunology)</term>
<term>Viral Envelope Proteins (immunology)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="chemical synthesis" xml:lang="en"><term>Peptides</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antibodies, Monoclonal</term>
<term>Peptides</term>
<term>Viral Envelope Proteins</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Simplexvirus</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Amino Acid Sequence</term>
<term>Animals</term>
<term>Antibody-Dependent Cell Cytotoxicity</term>
<term>Epitopes</term>
<term>Mice</term>
<term>Mice, Inbred Strains</term>
<term>Molecular Sequence Data</term>
<term>Neutralization Tests</term>
<term>Protein Conformation</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Herpes simplex virus (HSV) envelope glycoproteins are the prime targets of adaptive antiviral immunity. Previous investigation identified a protective, neutralizing, glycoprotein B1 (gB-1)-reactive monoclonal antibody (MAb B6) and localized the linear epitope recognized by the MAb to residue 84 of gB-1. Three overlapping peptides (two 20-mers and one 18-mer), together spanning amino acids 63 to 110 of the wild-type sequence of gB-1, were synthesized and analyzed for their ability to stimulate immunity which cross-reacts with HSV-1. All stimulated some level of response. Two peptides, the gB 18-mer and 20.1-mer, were recognized by MAb B6 and HSV-immune antibody but were unable to stimulate virus-neutralizing antibody or serum able to protect against zosteriform spread in vivo. The 20.2-mer peptide, however, which was not recognized by MAb B6 or HSV-generated immune antibody, stimulated the production of neutralizing antibody and serum able to protect against zosteriform spread. Immunization with all of the peptides was able to enhance viral clearance of a low dose of HSV-1 in an ear challenge model and induce antibody reactive in antibody-dependent complement-mediated lysis of HSV-1-infected cells in vitro. These results are the first report of HSV immunity induced by peptides corresponding to gB and indicate that the best immunogen, in terms of stimulating neutralizing antiserum able to protect in vivo against HSV-1, was a peptide not recognized by HSV-immune mechanisms or by the MAb used to localize it.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">1698994</PMID>
<DateCompleted><Year>1990</Year>
<Month>11</Month>
<Day>15</Day>
</DateCompleted>
<DateRevised><Year>2018</Year>
<Month>11</Month>
<Day>13</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">0022-538X</ISSN>
<JournalIssue CitedMedium="Print"><Volume>64</Volume>
<Issue>11</Issue>
<PubDate><Year>1990</Year>
<Month>Nov</Month>
</PubDate>
</JournalIssue>
<Title>Journal of virology</Title>
<ISOAbbreviation>J. Virol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Herpes simplex virus type 1-specific immunity induced by peptides corresponding to an antigenic site of glycoprotein B.</ArticleTitle>
<Pagination><MedlinePgn>5277-83</MedlinePgn>
</Pagination>
<Abstract><AbstractText>Herpes simplex virus (HSV) envelope glycoproteins are the prime targets of adaptive antiviral immunity. Previous investigation identified a protective, neutralizing, glycoprotein B1 (gB-1)-reactive monoclonal antibody (MAb B6) and localized the linear epitope recognized by the MAb to residue 84 of gB-1. Three overlapping peptides (two 20-mers and one 18-mer), together spanning amino acids 63 to 110 of the wild-type sequence of gB-1, were synthesized and analyzed for their ability to stimulate immunity which cross-reacts with HSV-1. All stimulated some level of response. Two peptides, the gB 18-mer and 20.1-mer, were recognized by MAb B6 and HSV-immune antibody but were unable to stimulate virus-neutralizing antibody or serum able to protect against zosteriform spread in vivo. The 20.2-mer peptide, however, which was not recognized by MAb B6 or HSV-generated immune antibody, stimulated the production of neutralizing antibody and serum able to protect against zosteriform spread. Immunization with all of the peptides was able to enhance viral clearance of a low dose of HSV-1 in an ear challenge model and induce antibody reactive in antibody-dependent complement-mediated lysis of HSV-1-infected cells in vitro. These results are the first report of HSV immunity induced by peptides corresponding to gB and indicate that the best immunogen, in terms of stimulating neutralizing antiserum able to protect in vivo against HSV-1, was a peptide not recognized by HSV-immune mechanisms or by the MAb used to localize it.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mester</LastName>
<ForeName>J C</ForeName>
<Initials>JC</Initials>
<AffiliationInfo><Affiliation>Department of Microbiology, College of Veterinary Medicine, University of Tennessee, Knoxville 37996-0845.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Highlander</LastName>
<ForeName>S L</ForeName>
<Initials>SL</Initials>
</Author>
<Author ValidYN="Y"><LastName>Osmand</LastName>
<ForeName>A P</ForeName>
<Initials>AP</Initials>
</Author>
<Author ValidYN="Y"><LastName>Glorioso</LastName>
<ForeName>J C</ForeName>
<Initials>JC</Initials>
</Author>
<Author ValidYN="Y"><LastName>Rouse</LastName>
<ForeName>B T</ForeName>
<Initials>BT</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y"><Grant><GrantID>AI 14982</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>AI 24762</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>J Virol</MedlineTA>
<NlmUniqueID>0113724</NlmUniqueID>
<ISSNLinking>0022-538X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000939">Epitopes</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D010455">Peptides</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014759">Viral Envelope Proteins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C040495">glycoprotein B, Simplexvirus</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000920" MajorTopicYN="N">Antibody-Dependent Cell Cytotoxicity</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000939" MajorTopicYN="N">Epitopes</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008815" MajorTopicYN="N">Mice, Inbred Strains</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009500" MajorTopicYN="N">Neutralization Tests</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010455" MajorTopicYN="N">Peptides</DescriptorName>
<QualifierName UI="Q000138" MajorTopicYN="N">chemical synthesis</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011487" MajorTopicYN="N">Protein Conformation</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018139" MajorTopicYN="N">Simplexvirus</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014759" MajorTopicYN="N">Viral Envelope Proteins</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1990</Year>
<Month>11</Month>
<Day>1</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>1990</Year>
<Month>11</Month>
<Day>1</Day>
<Hour>0</Hour>
<Minute>1</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>1990</Year>
<Month>11</Month>
<Day>1</Day>
<Hour>0</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">1698994</ArticleId>
<ArticleId IdType="pmc">PMC248567</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>J Mol Biol. 1978 Mar 25;120(1):97-120</Citation>
<ArticleIdList><ArticleId IdType="pubmed">642007</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Immunol. 1987 May 15;138(10):3431-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">3033075</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Exp Med. 1987 Feb 1;165(2):459-70</Citation>
<ArticleIdList><ArticleId IdType="pubmed">3029270</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 1987 May;155(5):914-20</Citation>
<ArticleIdList><ArticleId IdType="pubmed">3031173</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 1985 May 10;228(4700):737-40</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2986288</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Exp Med. 1985 Oct 1;162(4):1304-18</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2995536</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virology. 1989 Sep;172(1):11-24</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2475970</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virology. 1988 Oct;166(2):423-31</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2459843</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 1989 Feb;63(2):730-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2463380</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 1988 Jun;62(6):1881-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2452895</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 1986 Jul;59(1):142-53</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2423702</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virology. 1989 Mar;169(1):244-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2538036</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 1984 Dec;52(3):816-21</Citation>
<ArticleIdList><ArticleId IdType="pubmed">6092713</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 1987 Aug;84(16):5908-12</Citation>
<ArticleIdList><ArticleId IdType="pubmed">3303033</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Rev Infect Dis. 1980 Nov-Dec;2(6):899-913</Citation>
<ArticleIdList><ArticleId IdType="pubmed">6164087</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 1983 Feb;45(2):672-82</Citation>
<ArticleIdList><ArticleId IdType="pubmed">6187935</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virology. 1984 Mar;133(2):301-14</Citation>
<ArticleIdList><ArticleId IdType="pubmed">6324454</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Gen Virol. 1987 Apr;68 ( Pt 4):1103-14</Citation>
<ArticleIdList><ArticleId IdType="pubmed">3494812</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 1988 Feb;62(2):501-10</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2826811</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Curr Top Microbiol Immunol. 1986;130:51-64</Citation>
<ArticleIdList><ArticleId IdType="pubmed">3022991</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 1985 Dec;56(3):1014-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2999419</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 1986 Mar 13;314(11):686-91</Citation>
<ArticleIdList><ArticleId IdType="pubmed">3005858</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Gen Virol. 1974 Jul;24(1):17-27</Citation>
<ArticleIdList><ArticleId IdType="pubmed">4367302</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002A18 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 002A18 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= MersV1 |flux= PubMed |étape= Corpus |type= RBID |clé= pubmed:1698994 |texte= Herpes simplex virus type 1-specific immunity induced by peptides corresponding to an antigenic site of glycoprotein B. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:1698994" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \ | NlmPubMed2Wicri -a MersV1
![]() | This area was generated with Dilib version V0.6.33. | ![]() |